573 related articles for article (PubMed ID: 19029665)
1. Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization.
Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Sharifi Z
Hum Antibodies; 2008; 17(3-4):79-84. PubMed ID: 19029665
[TBL] [Abstract][Full Text] [Related]
2. Viral safety of solvent-detergent treated blood products.
Horowitz B; Prince AM; Horowitz MS; Watklevicz C
Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
[TBL] [Abstract][Full Text] [Related]
4. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
[TBL] [Abstract][Full Text] [Related]
5. Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation.
Roberts PL; Dunkerley C; Walker C
Biologicals; 2012 Sep; 40(5):345-52. PubMed ID: 22658506
[TBL] [Abstract][Full Text] [Related]
6. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
[TBL] [Abstract][Full Text] [Related]
7. Viral safety characteristics of Flebogamma DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin.
Caballero S; Nieto S; Gajardo R; Jorquera JI
Biologicals; 2010 Jul; 38(4):486-93. PubMed ID: 20350815
[TBL] [Abstract][Full Text] [Related]
8. Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates.
Korneyeva M; Hotta J; Lebing W; Rosenthal RS; Franks L; Petteway SR
Biologicals; 2002 Jun; 30(2):153-62. PubMed ID: 12127317
[TBL] [Abstract][Full Text] [Related]
9. Resistance of vaccinia virus to inactivation by solvent/detergent treatment of blood products.
Roberts P
Biologicals; 2000 Mar; 28(1):29-32. PubMed ID: 10799053
[TBL] [Abstract][Full Text] [Related]
10. Preparation, purification and virus inactivation of intravenous immunoglobulin from human plasma.
Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Banazadeh S
Hum Antibodies; 2010; 19(1):1-6. PubMed ID: 20555125
[TBL] [Abstract][Full Text] [Related]
11. Virus inactivation in a factor VIII/VWF concentrate treated using a solvent/detergent procedure based on polysorbate 20.
Roberts PL; Lloyd D; Marshall PJ
Biologicals; 2009 Jan; 37(1):26-31. PubMed ID: 18848782
[TBL] [Abstract][Full Text] [Related]
12. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
[TBL] [Abstract][Full Text] [Related]
13. Resistance of porcine circovirus and chicken anemia virus to virus inactivation procedures used for blood products.
Welch J; Bienek C; Gomperts E; Simmonds P
Transfusion; 2006 Nov; 46(11):1951-8. PubMed ID: 17076851
[TBL] [Abstract][Full Text] [Related]
14. Viral safety of a new highly purified factor VIII (OCTATE).
Biesert L; Lemon S; Goudeau A; Suhartono H; Wang L; Brede HD
J Med Virol; 1996 Apr; 48(4):360-6. PubMed ID: 8699169
[TBL] [Abstract][Full Text] [Related]
15. Inactivation and elimination of viruses during preparation of human intravenous immunoglobulin.
Uemura Y; Yang YH; Heldebrant CM; Takechi K; Yokoyama K
Vox Sang; 1994; 67(3):246-54. PubMed ID: 7863623
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of viruses and safety of stable plasma products.
Morgenthaler JJ
Beitr Infusionsther; 1989; 24():33-9. PubMed ID: 2481546
[TBL] [Abstract][Full Text] [Related]
17. Human intravenous immunoglobulin preparation and virus inactivation by pasteurization and solvent detergent treatment.
Chang CE; Eo HG; Lee YS; Chung SK; Shin JS; Lah YK; Park CW; Jung JT; Huh JW; Lee SM
Prep Biochem Biotechnol; 2000 Aug; 30(3):177-97. PubMed ID: 10919559
[TBL] [Abstract][Full Text] [Related]
18. [Viral safety considerations in immunoglobulin preparations].
Gómez Manzano P; Escrivá CA; Salmerón García F; Alonso Verduras C
Sangre (Barc); 1997 Jun; 42(3):199-203. PubMed ID: 9381262
[No Abstract] [Full Text] [Related]
19. Virus safety of pooled fresh-frozen plasma inactivated by solvent/detergent treatment.
Prince AM; Horowitz B
Beitr Infusionsther; 1993; 31():21-4. PubMed ID: 7693256
[No Abstract] [Full Text] [Related]
20. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process.
Furuya K; Murai K; Yokoyama T; Maeno H; Takeda Y; Murozuka T; Wakisaka A; Tanifuji M; Tomono T
Vox Sang; 2006 Aug; 91(2):119-25. PubMed ID: 16907872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]